TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36321229

Group type: EXPERIMENTAL
Intervention: Isokinetic exercise group (IKE)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional exercise group (CSE)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional exercise group
Number of subjects: 60
Study: 33939911

Group type: EXPERIMENTAL
Intervention: Allogenic ASC (1 × 10^6 cells/kg) + cholecalciferol (2,000 UI/day) for 6 months
Number of subjects: 7

Group type: COMPARATOR
Intervention: Cholecalciferol (group 2)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Standard treatment (group 3)
Number of subjects: 7
Study: 32960178

Group type: EXPERIMENTAL
Intervention: Mobile internet intervention for mothers and infants
Number of subjects: 86
Study: 35101704

Group type: EXPERIMENTAL
Intervention: Thread embedding acupuncture (TEA)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sham thread embedding acupuncture (STEA)
Number of subjects: 70
Study: 34654493

Group type: EXPERIMENTAL
Intervention: Articaine local infiltration
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lidocaine inferior alveolar nerve block (IANB)
Number of subjects: 30
Study: 33760691

Group type: EXPERIMENTAL
Intervention: Lidocaine with epinephrine (1:100,000)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Bacteriostatic normal saline
Number of subjects: 31
Study: 33432600

Group type: EXPERIMENTAL
Intervention: Reverse Trendelenburg position
Number of subjects: 110

Group type: COMPARATOR
Intervention: Semi-recumbent position
Number of subjects: 110
Study: 34391744

Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve repair (TMVr) plus guideline-directed medical therapy (GDMT)
Number of subjects: 614

Group type: COMPARATOR
Intervention: GDMT alone
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: TMVr
Number of subjects: 614
Study: 35265370

Group type: EXPERIMENTAL
Intervention: Customized Progressive Addition Lenses (CPALs)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Single Vision Lenses (SVLs)
Number of subjects: 93
Study: 35852098

Group type: EXPERIMENTAL
Intervention: Venetoclax in combination with oral azacitidine (CC‐486) as maintenance therapy
Number of subjects: 0
Study: 33787970

Group type: EXPERIMENTAL
Intervention: Machine learning-based analysis with contrast-enhanced CT
Number of subjects: 23
Study: 32791894

Group type: EXPERIMENTAL
Intervention: Olanzapine/samidorphan combination
Number of subjects: 561

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 561
Study: 34980285

Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment (CGA)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ED PLUS
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 30
Study: 32613634

Group type: EXPERIMENTAL
Intervention: Bilateral passive stretching
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Monolateral passive stretching
Number of subjects: 39

Group type: COMPARATOR
Intervention: No passive stretching (control)
Number of subjects: 39
Study: 36054086

Group type: EXPERIMENTAL
Intervention: Bilateral training (EXP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual training schedule (CONT)
Number of subjects: 60
Study: 33857594

Group type: EXPERIMENTAL
Intervention: Licorice nasal irrigation (LNI)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Corticosteroid nasal irrigation (CNI)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline nasal irrigation (SNI)
Number of subjects: 60
Study: 34034608

Group type: EXPERIMENTAL
Intervention: Lifestyle interventions (diet and physical activity components) initiated in the first half of pregnancy, delivered through multiple modalities (in-person visits, telephone calls, text messages, email) by trained intervention staff (dietitian, lifestyle coach, physiotherapist).
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Telehealth behavioral intervention for women with overweight or obesity.
Number of subjects: 4
Study: 33009729

Group type: EXPERIMENTAL
Intervention: Antivirals or treatment of complications (specifics not provided)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: World Health Organization's SOLIDARITY trial (specifics not provided)
Number of subjects: 0
Study: 35577631

Group type: EXPERIMENTAL
Intervention: 1 μg +/‐ CpG1018
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 3 μg alone
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 10 μg alone
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 32543080

Group type: EXPERIMENTAL
Intervention: Trigone-sparing Botox injection (100 IU intradetrusal)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Trigone-involved Botox injection (100 IU intradetrusal)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Both groups (Trigone-sparing and Trigone-involved)
Number of subjects: 103
Study: 32491154

Group type: EXPERIMENTAL
Intervention: Spousal influence
Number of subjects: 63
Study: 32814520

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients
Number of subjects: 289

Group type: COMPARATOR
Intervention: Community controls with impaired FPG
Number of subjects: 289

Group type: COMPARATOR
Intervention: Community controls
Number of subjects: 289
Study: 36130749

Group type: EXPERIMENTAL
Intervention: Religion-adapted ApBM
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard ApBM
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham ApBM
Number of subjects: 120
Study: 33337942

Group type: EXPERIMENTAL
Intervention: CBCT scans with voxel size 0.125
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CBCT scans with voxel size 0.200
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CBCT scans with voxel size 0.250
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CBCT scans with voxel size 0.300
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CBCT scans with voxel size 0.400
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CBCT scans with artifact reduction (AR)
Number of subjects: 100

Group type: COMPARATOR
Intervention: CBCT scans without artifact reduction (AR)
Number of subjects: 100
Study: 33571031

Group type: EXPERIMENTAL
Intervention: Prenatal individualized mixed management intervention (four sessions of psycho-education and breastfeeding education)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 182
Study: 33298104

Group type: EXPERIMENTAL
Intervention: Concentrated maple sap (MW)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Diluted maple syrup (MS)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo (P; water sweetened with stevia)
Number of subjects: 76
Study: 36341700

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 33517882

Group type: EXPERIMENTAL
Intervention: Additional daily physical therapy focused on mobility (n=99)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Additional social activities (n=99)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Additional daily physical therapy focused on mobility
Number of subjects: 198
Study: 37034563

Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance exercise training
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Number of subjects: 304

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 304
Study: 32956615

Group type: EXPERIMENTAL
Intervention: Supportive care, intravenous immunoglobulin, methylprednisolone, biological therapies (IL-1 antagonists, IL-6 receptor blockers, anti-TNF agents)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-1 antagonists (e.g., anakinra), IL-6 receptor blockers (e.g., tocilizumab), anti-TNF agents (e.g., infliximab)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rapid online Delphi process
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Consensus statements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New PIMS-TS specific treatment groups
Number of subjects: 0
Study: 32484940

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 100 μg/d
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 200 μg/d
Number of subjects: 54

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) high doses (≥1000 μg BID)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Budesonide (BUD) high doses (≥1500 μg BID)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Budesonide (BUD)
Number of subjects: 54
Study: 35750598

Group type: EXPERIMENTAL
Intervention: Xylitol gum chewing
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Nonxylitol gum chewing
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control
Number of subjects: 69
Study: 33261032

Group type: EXPERIMENTAL
Intervention: 3 mg·kg−1 caffeine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Non-ergogenic placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cognitive dual task
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Caffeine ingestion
Number of subjects: 12
Study: 36107516

Group type: EXPERIMENTAL
Intervention: Dance therapy using telerehabilitation (n = 9)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Conventional physical therapy (n = 8)
Number of subjects: 17
Study: 34119373

Group type: EXPERIMENTAL
Intervention: High mNUTRIC group (n = 46)
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Increased calorie intake (per 20% increase) in high mNUTRIC group
Number of subjects: 359
Study: 32058351

Group type: EXPERIMENTAL
Intervention: Directional microphone
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Directional microphone with noise reduction
Number of subjects: 19

Group type: COMPARATOR
Intervention: Omnidirectional microphone
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Omnidirectional microphone with noise reduction
Number of subjects: 19
Study: 33073879

Group type: EXPERIMENTAL
Intervention: Opicapone 25 mg
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Opicapone 50 mg
Number of subjects: 437

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 437
Study: 32703634

Group type: EXPERIMENTAL
Intervention: Fenofibrate (145 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 34363617

Group type: EXPERIMENTAL
Intervention: Prochlorperazine 10 mg IV plus diphenhydramine 25 mg IV
Number of subjects: 127

Group type: COMPARATOR
Intervention: Hydromorphone 1 mg IV
Number of subjects: 127
Study: 32436772

Group type: EXPERIMENTAL
Intervention: NEXTflex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NEBNext
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: QIAseq and TailorMix
Number of subjects: 0

Group type: COMPARATOR
Intervention: Synthetic miRNAs and human RNA
Number of subjects: 0
Study: 32142397

Group type: EXPERIMENTAL
Intervention: Partner playing poorly
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Partner having a good performance
Number of subjects: 103

Group type: COMPARATOR
Intervention: Partner perceived as playing their usual game (control group)
Number of subjects: 103
Study: 35487522

Group type: EXPERIMENTAL
Intervention: Menthol cigarettes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-menthol cigarettes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Menthol preference at baseline
Number of subjects: 0
Study: 34463869

Group type: EXPERIMENTAL
Intervention: Gemcitabine (GEM)
Number of subjects: 608

Group type: COMPARATOR
Intervention: Uracil-tegafur (UFT)
Number of subjects: 608
Study: 32901739

Group type: EXPERIMENTAL
Intervention: Clinical simulation as an educational strategy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual class
Number of subjects: 30
Study: 35334862

Group type: EXPERIMENTAL
Intervention: High-dose whey protein concentrate (WPC)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Low-dose whey protein concentrate (WPC)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Whey hydrolysate placebo
Number of subjects: 121
Study: 34132448

Group type: EXPERIMENTAL
Intervention: Motion observation therapy in virtual reality equipment combined with conventional cognitive training
Number of subjects: 118

Group type: COMPARATOR
Intervention: Conventional rehabilitation training
Number of subjects: 118
Study: 32095914

Group type: EXPERIMENTAL
Intervention: Social and economic equity
Number of subjects: 675

Group type: EXPERIMENTAL
Intervention: Family cohesion
Number of subjects: 675

Group type: EXPERIMENTAL
Intervention: Social support from friends
Number of subjects: 675
Study: 33200512

Group type: EXPERIMENTAL
Intervention: Roxadustat
Number of subjects: 415

Group type: COMPARATOR
Intervention: Darbepoetin alfa (DA)
Number of subjects: 415
Study: 35693254

Group type: EXPERIMENTAL
Intervention: Sandplay (SP) therapy
Number of subjects: 34

Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 34
Study: 33589135

Group type: EXPERIMENTAL
Intervention: Human endometrial biopsies
Number of subjects: 90
Study: 32178766

Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg every 4 weeks
Number of subjects: 741

Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg every 8 weeks
Number of subjects: 741

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 741
Study: 34642762

Group type: EXPERIMENTAL
Intervention: Free amino acids (30 g intrinsically l-[1-13C]-phenylalanine-labeled)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intact milk protein (30 g intrinsically l-[1-13C]-phenylalanine-labeled)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both free amino acids and intact milk protein
Number of subjects: 24
Study: 34516246

Group type: COMPARATOR
Intervention: MK-8507 (2 to 400 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MK-8507 (≥100 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: MK-8507 (400 mg once weekly)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Single and multiple doses of MK-8507
Number of subjects: 40
Study: 36253339

Group type: EXPERIMENTAL
Intervention: Infant massage (5 weeks, daily for at least 10 minutes)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (received intervention after study completion)
Number of subjects: 32
Study: 33892135

Group type: EXPERIMENTAL
Intervention: CMV-specific cytotoxic T-lymphocytes (CMV-CTLs)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard-of-care therapy
Number of subjects: 27
Study: 32948387

Group type: EXPERIMENTAL
Intervention: Double-needle lavage (DNL)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Double-needle lavage (DNL) with 2 needles at upper and lower extremes (B2)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Single-needle aspiration (SNA)
Number of subjects: 100
Study: 35793185

Group type: EXPERIMENTAL
Intervention: QLB+G group (30 mL of 0.375% ropivacaine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: G group (30 mL of 0.9% saline)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: QLB+G group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 0
Study: 33866032

Group type: EXPERIMENTAL
Intervention: Berotralstat 150 mg
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Berotralstat 110 mg
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo (Part 1)
Number of subjects: 108
Study: 33220855

Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19 (2·2 × 10^10 virus particles)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19 (standard-dose)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19 (single standard dose)
Number of subjects: 560

Group type: COMPARATOR
Intervention: MenACWY (control)
Number of subjects: 560
Study: 33252943

Group type: EXPERIMENTAL
Intervention: User-informed infographic (n = 75)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Standard EBT description (n = 77)
Number of subjects: 152
Study: 35834139

Group type: EXPERIMENTAL
Intervention: Shoulder Control programme
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Knee Control programme
Number of subjects: 627

Group type: COMPARATOR
Intervention: Control Group (usual training)
Number of subjects: 627
Study: 33206054

Group type: EXPERIMENTAL
Intervention: fooya! dietary mobile game
Number of subjects: 104
Study: 36366250

Group type: EXPERIMENTAL
Intervention: Vestibular Rehabilitation (VR)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional rehabilitation program
Number of subjects: 30
Study: 32989491

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 336107
Study: 34655319

Group type: EXPERIMENTAL
Intervention: Intra-operative manual correction of iliosacral dislocation of the sacroiliac joint
Number of subjects: 84

Group type: COMPARATOR
Intervention: Standard THA protocol
Number of subjects: 84
Study: 34198051

Group type: EXPERIMENTAL
Intervention: Phone on, in holder
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Phone off, in holder
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Phone on, in pocket
Number of subjects: 127

Group type: COMPARATOR
Intervention: Phone absent (control)
Number of subjects: 127
Study: 32398642

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24IU)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 34369981

Group type: EXPERIMENTAL
Intervention: Single session of electronic cigarette vaping
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long-term tobacco cigarette or electronic cigarette use
Number of subjects: 0
Study: 32260466

Group type: EXPERIMENTAL
Intervention: Schisandra Chinensis extract (1000 mg per day)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (1000 mg of starch per day)
Number of subjects: 45
Study: 33872802

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy for PTSD (IPT‐PTSD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prolonged Exposure (PE)
Number of subjects: 0
Study: 33106171

Group type: EXPERIMENTAL
Intervention: Melatonin capsules at a dose of 50 mg daily for a period of seven days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard therapeutic regimen for COVID-19
Number of subjects: 60

Group type: COMPARATOR
Intervention: Melatonin-like placebo capsules at a dose of one capsule daily for a period of seven days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Melatonin and standard treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo and standard treatment
Number of subjects: 60
Study: 35271380

Group type: EXPERIMENTAL
Intervention: Infants receiving direct vitamin D supplementation (400 IU vitD3/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Infants receiving indirect vitamin D supplementation via mothers (mothers receiving 6,400 IU vitD3/day)
Number of subjects: 0
Study: 33300311

Group type: EXPERIMENTAL
Intervention: Total laparoscopic nerve-sparing radical hysterectomy (TL-NSRH)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Open abdominal nerve-sparing radical hysterectomy (OA-NSRH)
Number of subjects: 301
Study: 36458679

Group type: EXPERIMENTAL
Intervention: Desidustat 50 mg orally in a fasting state
Number of subjects: 0

Group type: COMPARATOR
Intervention: Desidustat 50 mg orally in a fed state
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desidustat 50 mg orally
Number of subjects: 0
Study: 33180360

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Number of subjects: 38
Study: 35075017

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided bilateral erector spinae plane block (ESP block)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Thoracic Epidural Analgesia (TEA)
Number of subjects: 20
Study: 34494517

Group type: EXPERIMENTAL
Intervention: Ultra-fast track cardiac anaesthesia (Group D) with dexmedetomidine at 1 ?g/kg/hour and sufentanil for analgesia
Number of subjects: 130

Group type: COMPARATOR
Intervention: Conventional anaesthesia (Group C) with normal saline and sufentanil for analgesia
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Ultra-fast track cardiac anaesthesia (Group D)
Number of subjects: 130
Study: 35148706

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) counseling in 8 sessions of 60 to 90 minutes
Number of subjects: 86

Group type: COMPARATOR
Intervention: Routine health care (Control)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) counseling
Number of subjects: 86
Study: 32822275

Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg intravenously every 2 weeks)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Nivolumab plus SBRT (9 Gy × 3 to 1 lesion)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 62
Study: 35441435

Group type: COMPARATOR
Intervention: Placebo plus diet
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Empagliflozin only
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Empagliflozin plus diet
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo only
Number of subjects: 68
Study: 33376050

Group type: EXPERIMENTAL
Intervention: Greek IdFAI questionnaire (IdFAI-GR)
Number of subjects: 141
Study: 34973306

Group type: EXPERIMENTAL
Intervention: PEEP applied at 10 cmH20
Number of subjects: 80

Group type: COMPARATOR
Intervention: No PEEP application (Control)
Number of subjects: 80
Study: 36164101

Group type: EXPERIMENTAL
Intervention: Zanubrutinib 160 mg twice daily
Number of subjects: 229

Group type: COMPARATOR
Intervention: Ibrutinib 420 mg once daily
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Number of subjects: 229

Group type: COMPARATOR
Intervention: Ibrutinib
Number of subjects: 229
Study: 34770227

Group type: EXPERIMENTAL
Intervention: Healing Beats program
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control
Number of subjects: 99
Study: 32164678

Group type: EXPERIMENTAL
Intervention: Culturally responsive best practice model of care including development of a best practice guide, education programs for health professionals, and decision support systems.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Culturally responsive best practice model of care
Number of subjects: 0
Study: 35833334

Group type: EXPERIMENTAL
Intervention: Erythropoietin (ESA) treatment
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Intravenous iron treatment
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Four-variable iron preference score
Number of subjects: 197